Peptide Bioregulators: The Khavinson Protocol and What the Evidence Shows

When people first encounter the term peptide bioregulators, the most common reaction is confusion — are these the same as the peptides they already know about, like BPC-157 or thymosin alpha-1? The short answer is no. Peptide bioregulators are a distinct class: ultra-short (2–4 amino acid) organ-specific peptides and organ extracts developed over five decades at the St. Petersburg Institute of Bioregulation and Gerontology, principally by Professor Vladimir Khavinson. Their proposed mechanism of action is epigenetic rather than receptor-mediated, and their evidence base comes largely from one research programme, much of it published in Russian-language journals.

The Khavinson group’s cohort of 266 older adults who received Thymalin and Epithalamin is one of the few peptide longevity studies that reports mortality at all. That earns it a careful read. What follows is an honest review: what the compounds are, how the protocol is used, and where the evidence is thin.

At a Glance

What Are Peptide Bioregulators?

The bioregulator concept originates from Khavinson’s observation in the 1970s that organ-specific extracts from young animals appeared to improve organ function in old animals. The group later identified very short peptides in those extracts and synthesised analogues.

Two product lines emerged:

• Cytomax peptides — natural extracts from animal organs, standardized and marketed under names such as Thymalin (thymus extract), Cortexin (cerebral cortex), Epithalamin (pineal gland) and Ventfort (blood-vessel extract)
• Cytogen (synthetic) peptides — chemically synthesized analogs: Epithalon (Ala-Glu-Asp-Gly), Pinealon (Glu-Asp-Arg), Cortagen (Ala-Glu-Asp-Pro), Crystagen (Glu-Asp-Pro), Vesugen (Lys-Glu-Asp), among others

The synthetic versions are shorter (typically 4 amino acids or fewer), more reproducible, and increasingly available through international peptide compounders.

How They Work: The Proposed Epigenetic Mechanism

The proposed mechanism — and the reason these compounds are genuinely interesting — is epigenetic rather than the receptor-binding or growth-factor signaling seen with most therapeutic peptides. The group reports that these short peptides enter the cell nucleus, bind histones and DNA, and change gene expression. In one cell study, Epithalon (AEDG) increased markers of neuronal differentiation in human gingival stem cells, and molecular modelling suggested binding to histone H1 [5]. In another, adding Epithalon to telomerase-negative human fetal fibroblasts induced telomerase activity and telomere elongation [3].

These are interesting laboratory findings. They show a possible mechanism. They do not yet show that the peptides make human organs younger.

What the Evidence Shows

Preclinical

The mouse data are mixed rather than uniformly positive: in the best-described Epithalon life-span study, mean life span did not change [4].

Human

The 266-person study is often described online as a “15-year mortality RCT”. The published abstract describes 266 people observed for 6-8 years [1]. Whatever the full methods, a single unreplicated study from the developers cannot carry all the weight that is put on it.

The Key Bioregulators: Organ by Organ

For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.

Thymalin — Thymus Bioregulator

Thymalin is the most extensively studied of the natural Cytomax extracts. It is a polypeptide complex derived from calf thymus.

Evidence: The key study is the Khavinson/Morozov cohort of 266 older adults described above: Thymalin, Epithalamin or both were given during the first 2-3 years, and the treated groups had fewer respiratory infections and lower mortality over 6-8 years of observation [1].

Clinical use: Immune senescence, post-infectious immune reconstitution, thymic involution in people over 50. Thymalin is most often considered when lymphocyte subset testing shows impaired T-cell maturation, particularly CD4:CD8 ratios below 1.5 with low CD28+ naive T-cells — a pattern consistent with thymic atrophy.

Protocol: 10 mg/day IM for 10 days, repeated twice yearly. Some practitioners use oral enteric-coated capsules; bioavailability is lower but convenience is higher.

Epithalon (Epitalon) — Pineal Bioregulator

Epithalon (Ala-Glu-Asp-Gly) is the synthetic tetrapeptide analog of Epithalamin, the natural pineal extract. It is the most widely used bioregulator outside Russia, partly because of its telomerase-activation data.

Evidence: Telomerase activation in human fibroblast culture [3]; in mice, mean life span did not change while maximum life span increased [4]; the group’s review reports larger life-span gains for some preparations [2]. Human data come primarily from Khavinson’s group. See the Epithalon dosage page for the full evidence and the open cancer question.

Clinical use: Age-related circadian disruption, melatonin support, telomere support programs.

Protocol: 5–10 mg/day SC or IM for 10–20 days; or 20 mg sublingually. Typically two courses per year. Some protocols use it daily at 2–5 mg for shorter courses (10 days) repeated quarterly.

Pinealon (Glu-Asp-Arg) — Synthetic Pineal Tripeptide

Pinealon is the synthetic tripeptide for the pineal-brain axis, with a more neuro-protective focus than Epithalon. The Khavinson group reports neuroprotective effects in experimental models.

Clinical use: Cognitive aging, neurological protection, circadian support. Pinealon is typically chosen over Epithalon when the primary concern is cognitive preservation rather than telomere/longevity protocol integration.

Full profile: Pinealon (EDR): evidence and dosing.

Cortagen (Ala-Glu-Asp-Pro) — Cerebral Cortex Bioregulator

Cortagen is a synthetic tetrapeptide targeting cortical neurons. The developing group reports improved learning, memory consolidation, and EEG normalization, mainly in animal work. It is often used alongside Pinealon for combined cortical and pineal support.

Clinical use: Age-related cognitive decline, post-COVID brain fog with verified cognitive impairment on testing, recovery from prolonged illness with neurological residua.

Full profile: Cortagen (AEDP): evidence and dosing.

Ventfort — Vascular Bioregulator (Natural Extract)

Ventfort is a Cytomax: a peptide complex extracted from animal blood-vessel tissue, aimed at vascular smooth muscle and endothelial cells. It is not a defined tripeptide. The sequence Glu-Asp-Pro that is sometimes attached to it belongs to Crystagen, the synthetic immune Cytogen; the synthetic vascular Cytogen is Vesugen (Lys-Glu-Asp). Russian studies report modest reductions in LDL oxidation and improvements in endothelial function markers.

Clinical use: Vascular aging, atherosclerosis prevention programs, people with elevated hsCRP and early endothelial dysfunction on pulse wave velocity testing.

Pancragen (Lys-Glu-Asp-Trp) — Pancreatic Bioregulator

Pancragen targets pancreatic β-cells and exocrine tissue. The developing group reports improved insulin secretion dynamics and reduced oxidative stress in pancreatic cells.

Clinical use: Early type 2 diabetes or pre-diabetes with suspected β-cell decline, metabolic syndrome. It is sometimes paired with berberine as part of a broader metabolic protocol.

The Khavinson Protocol: Practical Implementation

For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.

The standard approach from the Khavinson group uses cyclic courses — typically 10 days on, followed by a rest period, with two to three courses per year. The rationale for cycling rather than continuous dosing is that the epigenetic response is initiated during the treatment window and then consolidates during the rest period. Continuous dosing is not believed to provide additional benefit and may theoretically downregulate the target pathways.

A general adult longevity protocol (commonly referenced in the literature):

Oral enteric-coated formulations (marketed as Bonismart, Endoluten, Vladonix, etc.) are available and used widely in self-experimenting longevity communities. The proposed rationale is that the short peptides can survive gastric transit when encapsulated, though injection remains the standard for reproducible dosing.

How They Fit Into a Longevity Plan

Bioregulators make most sense as one part of a structured longevity plan, not as standalone treatments — for people aged 50+ who are already optimizing the fundamentals (sleep, metabolic health, inflammation burden) and want to add organ-specific support. The most common starting combination is Epithalon + Thymalin, run as concurrent 10-day courses twice yearly, with an organ-specific peptide added for a specific cognitive, vascular or metabolic concern. It helps to agree in advance how response will be tracked — the same biomarkers used at baseline (biological age estimates, immune subsets, metabolic panel) plus symptoms — and what would count as no effect. The expected effect size is modest by the standards of pharmacological interventions such as GLP-1 agonists.

Safety Profile and Risks

Few adverse events have been reported in the Khavinson programme, but those reports come from the same group that developed the products. Absence of reported harm is not the same as demonstrated safety.

• Unknown long-term safety. No independent long-term safety data exist.
• Autoimmune disease: Thymalin and other thymus-derived extracts are intended to change immune function and could theoretically exacerbate autoimmune conditions; their effect has not been properly studied. They are generally avoided in active Hashimoto’s flares and in active autoimmune disease.
• Malignancy: No carcinogenic signal has been reported in the group’s literature, and some of its animal studies report fewer tumours. Long-term oncological safety data are absent, and for Epithalon a 2025 cell study found telomere lengthening in breast cancer cell lines [6], so a current or past cancer calls for caution.
• Animal-derived extracts. Tissue extracts raise questions of standardisation and biological contamination that synthetic peptides do not.
• Product quality. For epitalon, the FDA states that compounded drugs may pose risk for immunogenicity due to aggregation and peptide-related impurities, and that it has not identified safety-related information for the proposed route. Injections also carry a risk of infection.
• Pregnancy: No data; avoid.
• Drug interactions: No documented pharmacokinetic interactions. The ultra-short peptides do not appear to be CYP450 substrates.
• Opportunity cost. Bioregulator courses should not displace interventions with strong evidence for healthy aging, such as physical activity, blood pressure and lipid control, and vaccination.

Limitations of the Evidence Base

Intellectual honesty requires acknowledging what this body of evidence is not. The overwhelming majority of studies come from a single research group at a single institution, much of it in Russian-language journals. Independent replication in peer-reviewed journals is essentially absent. The 266-person mortality cohort was run by the developers, its randomisation and blinding are not described in the abstract, and it would not pass modern RCT reporting standards (CONSORT, pre-registration).

This does not make the evidence worthless. Long-term follow-up with a plausible mechanism is more than many longevity interventions can claim. But the evidence sits at “promising with a coherent mechanism” rather than “proven by multiple independent trials.”

Regulatory Status

• FDA (US): none of these products is FDA-approved. Epitalon appears on the FDA page of bulk substances that may present significant safety risks in compounding (content current as of 22 April 2026), among substances previously in category 2 whose nominations were withdrawn. It is not on the 503A bulks list or in category 1 on the FDA list updated 14 May 2026.
• EMA / Germany: not authorised as medicines by the EMA or Germany’s BfArM. Supplement-style capsules do not require proof of efficacy before sale, and a “research use only” label does not make a product approved or tested for human use.
• Russia: some tissue extracts have been used as medicines there; check the national registry if this matters to you.
• WADA 2026: not named individually; non-approved substances fall under S0.

When to Talk to a Physician

If you are interested in bioregulators because of immune aging, poor sleep, cognitive worries or general vitality, have each of those problems evaluated on its own terms first; each has an evaluation pathway and treatments with better evidence. If you are already taking bioregulator products, tell your doctor which ones, how you take them and where they come from, especially if you have an autoimmune disease, cancer or are pregnant.

Seek prompt care for fever or spreading redness at an injection site, or any allergic reaction.

The Bottom Line

The Khavinson programme produced a coherent hypothesis, a cyclic protocol (typically 10-20 day courses about twice a year), and some intriguing cell and animal results. The human evidence rests largely on one developer-run cohort of 266 older adults that has never been independently replicated. That places peptide bioregulators in the “promising but unconfirmed” category: worth proper trials, and worth an informed, carefully monitored decision for anyone considering them.

Related Articles

• Thymosin Alpha-1: The Immune Modulator with Real Data
• Epithalon Dosage and Cycling Protocols
• Peptide Therapy for Women: What Changes and What Doesn’t
• Peptide Stacking Guide
• NAD+ IV Therapy: What to Expect

Individual Bioregulator Profiles

• Bronchogen (AEDL): lung bioregulator
• Cardiogen (AEDR): heart bioregulator
• Cartalax (AED): cartilage bioregulator
• Cortagen (AEDP): brain-cortex bioregulator
• Crystagen (EDP): immune bioregulator
• Livagen (KEDA): liver bioregulator
• Ovagen (EDL): liver and gut bioregulator
• Pinealon (EDR): brain bioregulator
• Prostamax (KEDP): prostate bioregulator
• Testagen (KEDG): marketed testicular bioregulator
• Thymogen (Glu-Trp): thymus dipeptide
• Vesugen (KED): vascular bioregulator
• Vilon (Lys-Glu): thymus dipeptide